Last edition
News about "Subcutaneous Sabirnetug "
Acumen Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug
Acumen Pharmaceuticals, Inc. has announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study.
Subcutaneous Sabirnetug | 03/08/2024 | By Aishwarya | 133
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members